Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study

Basit Öğe Kaydı
dc.authorscopusid55987915300
dc.authorscopusid57193238894
dc.authorscopusid6504396778
dc.authorscopusid57217125486
dc.authorscopusid57194440555
dc.authorscopusid23059468500
dc.authorscopusid15840660900
dc.contributor.authorKostek O.
dc.contributor.authorKucukarda A.
dc.contributor.authorTozkir H.
dc.contributor.authorNihat Okten I.
dc.contributor.authorOzden E.
dc.contributor.authorCabuk D.
dc.contributor.authorSari M.
dc.date.accessioned2024-06-12T10:28:26Z
dc.date.available2024-06-12T10:28:26Z
dc.date.issued2021
dc.description.abstractPurpose: To demonstrate the clinical and demographic findings of the patients harboring BRCA1/2 mutations with breast, genital tract, prostate and pancreas cancers. Methods: The results of sequencing analysis of 200 cancer patients (190 women, 10 men) who had been directed to genetic counseling with an indication BRCA1/ BRCA2 testing from different regions across 9 medical oncology centers were retrospectively analyzed. Results: A total of 200 consecutive cancer patients who harbored BRCA1/BRCA2 mutation [130 (65%) patients harbored BRCA 1 mutation, and 70 harbored BRCA 2 mutation] were included. Of these, 64.0% had breast cancer, 31.5% had genital cancers, 3.5% had prostate and 1.0% had pancreatic cancers. The age at diagnosis [57 (IQR 50-66) years] of parents who had BRCA mutant cancer was higher than the age of their children who had BRCA mutant cancer [median age 45 (IQR 38-45) years]. BRCA2 carriers with ovarian cancer had favorable survival outcomes. In ovarian cancer patients, progression-free survival longer than 12 months was significantly more frequent in BRCA2 carriers compared with those in BRCA1 carriers. Conclusions: Newly diagnosed BRCA 1/2 carriers with cancers were younger than their parents who harbored BRCA mutation with cancer. The findings from Turkish BRCA 1/2 associated cancer patients suggest that earlier onset of the screening program and genetic counseling of BRCA associated patients and their family members are essential to earlier disease diagnosis and to prevent disease occurrence as well. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage2661en_US
dc.identifier.issn1107-0625
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85123535142en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2654en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17250
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrca1; Brca2; Breast; Genital Cancers; Pancreas; Pancreas; Prostateen_US
dc.subjectAbiraterone; Brca1 Protein; Brca2 Protein; Cabazitaxel; Docetaxel; Enzalutamide; Olaparib; Adult; Article; Breast Cancer; Cancer Chemotherapy; Cancer Patient; Cancer Survival; Controlled Study; Ecog Performance Status; Family History; Female; Gene Mutation; Genital Tract Cancer; Histopathology; Human; Lymph Node Metastasis; Major Clinical Study; Male; Middle Aged; Multicenter Study; Multiple Primary Neoplasm; Ovary Cancer; Pancreas Cancer; Progression Free Survival; Prostate Cancer; Retrospective Studyen_US
dc.titleBreast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu